← brief for 2026-08-13 · Slowing decline

ARANESP

Key takeaways

This trial showed EPO reduces anemia risk but not quality of life. It was a small trial with 50 patients for 6 months.

Who did this work

Amgen, Inc

Source

Paper · openFDA, renal drug labels · 2026-07-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9